Healthcare -
Biotechnology - NASDAQ - US
$ 63.0
-1.28 %
$ 3.47 B
Market Cap
-21.07
P/E
1. INTRINSIC VALUE
Balance Sheet
Arcellx, Inc.
| Current Assets | 599 M |
| Cash & Short-Term Investments | 588 M |
| Receivables | 0 |
| Other Current Assets | 11.7 M |
| Non-Current Assets | 112 M |
| Long-Term Investments | 38.3 M |
| PP&E | 70.2 M |
| Other Non-Current Assets | 3.5 M |
| Current Liabilities | 125 M |
| Accounts Payable | 2.1 M |
| Short-Term Debt | 7.54 M |
| Other Current Liabilities | 116 M |
| Non-Current Liabilities | 131 M |
| Long-Term Debt | 46.5 M |
| Other Non-Current Liabilities | 84.6 M |
EFFICIENCY
Earnings Waterfall
Arcellx, Inc.
| Revenue | 108 M |
| Cost Of Revenue | 0 |
| Gross Profit | 103 M |
| Operating Expenses | 246 M |
| Operating Income | -138 M |
| Other Expenses | -30.2 M |
| Net Income | -107 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Arcellx, Inc.
| Net Income | -107 M |
| Depreciation & Amortization | -10.3 M |
| Capital Expenditures | -13.4 M |
| Stock-Based Compensation | 61.1 M |
| Change in Working Capital | -30.8 M |
| Others | -42.3 M |
| Free Cash Flow | -96.9 M |
Wall Street Analysts Price Targets
Arcellx, Inc.
Wall Street analysts predict an average 1-year price target for ACLX of $112 , with forecasts ranging from
a
low of
$95 to a high of $122 .
ACLX Lowest Price Target
Wall Street Target
95 USD
50.79%
ACLX Average Price Target
Wall Street Target
112 USD
77.14%
ACLX Highest Price Target
Wall Street Target
122 USD
93.65%
4. DIVIDEND
ANALYSIS
ACLX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Arcellx, Inc.
Sold
0-3 MONTHS
1.16 M USD 2
3-6 MONTHS
15 M USD 4
6-9 MONTHS
7.93 M USD 2
9-12 MONTHS
10.1 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at.
businesswire.com
- 1 month ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.
businesswire.com
- 1 month ago
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.14 per share a year ago.
zacks.com
- 1 month ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.
seekingalpha.com
- 1 month ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
seekingalpha.com
- 1 month ago
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare.
businesswire.com
- 3 months ago
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University.
globenewswire.com
- 3 months ago
Arcellx Impressive Safety Data Leaves Doubts
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
seekingalpha.com
- 3 months ago
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to earnings of $0.42 per share a year ago.
zacks.com
- 3 months ago
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors s.
businesswire.com
- 3 months ago
5 Biotech Breakthrough Stocks to Watch in 2025
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
zacks.com
- 6 months ago
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. The post Arcellx And Legend Bio Trade Jabs In Multiple Myeloma.
investors.com
- 6 months ago
8. Profile
Summary
Arcellx, Inc. ACLX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 3.47 B
Dividend Yield
0.00%
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Contact
25 West Watkins Mill Road, Redwood City, MD, 20878
https://arcellx.com
IPO
Date
Feb. 4, 2022
Employees
163
Officers
Ms. Kate Aiken
Chief People Officer
Ms. Maryam Abdul-Kareem J.D., M.S.
General Counsel & Chief Legal Officer
Ms. Aileen Fernandes
Chief Business Officer
Mr. Narinderjeet Singh M.S.
Chief Technical Officer
Dr. Christopher R. Heery M.D.
Chief Medical Officer
Ms. Myesha Lacy
Chief Investor & Communications Officer
Mr. Neeraj P. Teotia
Chief Commercial Officer
Dr. Heba Nowyhed Ph.D.
Chief Scientific Officer
Mr. Rami Elghandour
Chairman of the Board, Chief Executive Officer & President
Ms. Michelle Lim Gilson
Chief Financial Officer